CRIP2

Across TCGA pan-cancer cohorts, CRIP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRIP2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CRIP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRIP2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where CRIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.771	0.998	.008	16	view →
CCRCC	DFS	Tertile	III,IV	0.879	0.557	.020	11	view →
PDAC	OS	Tertile	IV	0.916	0.231	.024	6	view →
LUAD	DFS	Quartile	All	0.838	1.000	.004	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRIP2–LSCC (DFS)

Open the LSCC breakdown →